二甲双胍治疗C11orf65基因多态性2型糖尿病患者颈动脉内膜中层厚度变化的研究

Changes of carotid intima-media thickness in type 2 diabetic patients with C11orf65 gene polymorphism and treated with Metformin

目的探讨二甲双胍治疗C11orf65基因多态性T2DM患者颈动脉内膜中层厚度(CIMT)的变化。方法选取2020年2月至2021年8月于福建医科大学附属南平第一医院内分泌科治疗的新诊断T2DM患者282例。根据C11orf65 rs11212617基因型将二甲双胍单药治疗的T2DM患者分为CC(n=120)、CA(n=120)及AA型(n=42)共3组。收集二甲双胍治疗前后一般资料及相关指标,检测C11orf65基因型多态性、HbA1c、CIMT等。结果282例患者基因型分布符合Hardy-Weinberg遗传平衡。二甲双胍治疗后CC基因型低于CA、AA基因型[(1.43±0.65)vs(1.64±0.66)vs(1.65±0.67)mm,P<0.05]。多因素线性回归分析结果显示,C11orf65基因型多态性是二甲双胍治疗前后CIMT变化的影响因素。结论T2DM患者C11orf65基因多态性影响二甲双胍调控血糖,与动脉粥样硬化相关。

Objective To investigate the changes of carotid intima-media thickness(CIMT)in patients with type 2 diabetes mellitus(T2DM)and C11orf65 gene polymorphism and treated with Metformin.Methods A total of 282 T2DM patients with T2DM were enrolled in this study from the First Hospital of Nanping Affiliated to Fujian Medical University from February 2020 to August 2021.All the patients were treated with Metformin monotherapy and divided into three groups according to their genotypes of C11orf65rs11212617:CC(n=120),CA(n=120)and AA(n=42)group.General data and relevant indicators were collected before and after Metformin treatment.Glycosylated hemoglobin(HbA1c)and CIMT were measured.Results The genotype distribution was consistent with Hardy-Weinberg genetic balance in all the 282 study subjects.After Metformin treatment,CIMT were significantly lower in CC genotype group than in CA and AA genotype[(1.43±0.65)vs(1.64±0.66)vs(1.65±0.67)mm,P<0.05].Multi-factor linear regression analysis showed that C11orf65 genotype polymorphism was an influencing factor for CIMT changes before and after Metformin treatment.Conclusion C11orf65 gene polymorphism may affect the regulation of blood glucose with Metformin,which may associated with atherosclerosis in T2DM patients.